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Asymmetric Deactivation of HIV-1 gp41 following Fusion
Inhibitor Binding
Kristen M. Kahle, H. Kirby Steger¤, Michael J. Root*
Department of Biochemistry and Molecular Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
Abstract
Both equilibrium and nonequilibrium factors influence the efficacy of pharmaceutical agents that target intermediate states
of biochemical reactions. We explored the intermediate state inhibition of gp41, part of the HIV-1 envelope glycoprotein
complex (Env) that promotes viral entry through membrane fusion. This process involves a series of gp41 conformational
changes coordinated by Env interactions with cellular CD4 and a chemokine receptor. In a kinetic window between CD4
binding and membrane fusion, the N- and C-terminal regions of the gp41 ectodomain become transiently susceptible to
inhibitors that disrupt Env structural transitions. In this study, we sought to identify kinetic parameters that influence the
antiviral potency of two such gp41 inhibitors, C37 and 5-Helix. Employing a series of C37 and 5-Helix variants, we
investigated the physical properties of gp41 inhibition, including the ability of inhibitor-bound gp41 to recover its fusion
activity once inhibitor was removed from solution. Our results indicated that antiviral activity critically depended upon
irreversible deactivation of inhibitor-bound gp41. For C37, which targets the N-terminal region of the gp41 ectodomain,
deactivation was a slow process that depended on chemokine receptor binding to Env. For 5-Helix, which targets the C-
terminal region of the gp41 ectodomain, deactivation occurred rapidly following inhibitor binding and was independent of
chemokine receptor levels. Due to this kinetic disparity, C37 inhibition was largely reversible, while 5-Helix inhibition was
functionally irreversible. The fundamental difference in deactivation mechanism points to an unappreciated asymmetry in
gp41 following inhibitor binding and impacts the development of improved fusion inhibitors and HIV-1 vaccines. The
results also demonstrate how the activities of intermediate state inhibitors critically depend upon the final disposition of
inhibitor-bound states.
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Introduction
Intermediate states of biological processes are increasingly
common targets for inhibition [1,2]. The transient nature of such
targets makes inhibitory potency a complex function of both
equilibrium and nonequilibrium factors [3]. Here, we characterize
the intermediate-state inhibition of HIV-1 gp41, part of the Env
glycoprotein complex that mediates viral entry through membrane
fusion. The process is coordinated by sequential binding of Env
subunit gp120 to cellular CD4 and a chemokine receptor such as
CXCR4 or CCR5 (Figure 1A) [4]. These events trigger
rearrangements of the gp41 ectodomain that culminate in
formation of a compact structure known as the trimer-of-hairpins
(TOH) [5,6]. Molecules that block TOH formation can effectively
inhibit HIV-1 membrane fusion both in vitro and in vivo.
The primary targets for gp41 inhibitors are two heptad repeat
(HR) segments in the N- and C-terminal regions of the gp41
ectodomain (denoted N-HR and C-HR, respectively) [7]. In the
fusogenic TOH conformation, these HR regions form a stable
bundle of six a-helices: N-HR segments from three gp41
ectodomains form a trimeric coiled coil, around which the three
C-HR segments pack in an antiparallel manner into hydrophobic
grooves on the coiled-coil surface [5,6]. Inhibitors bind the N-HR
or C-HR segment prior to bundle formation and prevent collapse
of gp41 into its TOH conformation [4]. The best characterized
are linear peptides derived from the C-HR and adjacent regions of
the gp41 ectodomain [7–9]. Denoted C-peptides, these agents
target the N-HR in its coiled-coil conformation, binding the same
hydrophobic grooves that would normally interact with gp41 C-
HR segments [10,11]. One C-peptide, T20 (enfuvirtide) effectively
suppresses HIV-1 infection in humans and is currently used as
salvage therapy for AIDS patients refractory to other antiviral
medications [12,13]. In a complementary manner, engineered
proteins that structurally mimic all or part of the N-HR coiled coil
can inhibit HIV-1 entry by binding the gp41 C-HR segments
[14,15]. A well characterized example is the 5-Helix protein,
which contains all three N-HR segments but only two C-HR
segments; when properly folded, 5-Helix exposes a single C-
peptide binding site that strongly interacts with gp41 C-HR
regions [16].
C-peptides and 5-Helix do not interact with the native state of
Env prior to gp120/CD4 interaction [3,17,18]. Rather, these
inhibitors target an intermediate state that exists in a kinetic window
between gp120/CD4 binding and TOH formation [19–21].
Evidence suggests that the gp41 ectodomain in this transient
prehairpin state adopts an extended conformation, with its N-
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terminus (called the fusion peptide) inserted in the target cell
membrane, its transmembrane region embedded in the viral
membrane, and its N-HR coiled coil and C-HR segments exposed
to bulk solution (Figure 1A) [22]. Despite the kinetic restrictions of
targeting a transient conformation, gp41 inhibitors can possess
potent (low nanomolar to high picomolar) antiviral activity [8,23].
Because gp41 inhibitors target a transient intermediate state,
their potency is not simply determined by equilibrium binding
affinity [3,19,21]. Nonequilibrium parameters, such as the rate of
inhibitor association and the lifetime of the intermediate state also
influence the degree of inhibition. Previously, we showed that the
potency of 5-Helix was primarily determined by these kinetic
properties: for a series of 5-Helix variants with mutations in their
gp41 binding sites, IC50 values varied inversely with association
rate constants (kon), but showed poor correlation with equilibrium
dissociation constants (KD) [3]. Here, we unexpectedly found that
the opposite relationship held true for a C-peptide inhibitor: IC50
values for a series of C37 variants depended in large part on
binding affinity, but did not correlate with kon. Thus, despite
targeting the same intermediate state, the physical properties
underlying 5-Helix and C37 inhibition were fundamentally
different. We linked this discrepancy to the ultimate disposition
of Env following inhibitor binding and employed this knowledge to
design novel C37 inhibitors that retained potent antiviral activity
in the setting of C-peptide escape mutations.
Results
Physical Properties of 5-Helix and C37 Inhibition
We investigated how the antiviral potencies of 5-Helix and C37
inhibition were impacted by Ala and Asp substitutions at residue
positions that contact gp41. Concurrently, we used a bimolecular 5-
Helix/C37 interaction assay to measure the effect of mutations on
the binding affinities and association rates of these inhibitor variants
(see Materials and Methods, Figure S1). In a previous study
employing cell-cell fusion experiments, IC50 values for a series of 5-
Helix variants poorly correlated with KD but showed a strong
inverse dependence on kon [3]. Here, we found the same behavior
was quantitatively maintained in viral infectivity assays (Figure 1B,
D; Table S1). Specifically, the degree of affinity disruption caused
by the mutations was not predictive of 5-Helix antiviral activity. For
instance, 5-Helix and 5-HelixV549A/L556A/Q563A had very similar
IC50 values (11 and 16 nM, respectively) despite the 50,000-fold
difference in their KD values (0.00065 and 29 nM, respectively).
Furthermore, IC50 values for 5-HelixV549A/L556A/Q563A (16 nM)
and 5-HelixV549D/L556A (2400 nM) were very different, even
though their KD values were comparable (29 versus 40 nM,
respectively). Rather, we found that antiviral activity closely
tracked with inhibitor association rate: potent inhibitors 5-Helix
and 5-HelixV549A/L556A/Q563A shared similarly high kon values
(,36107 M21 sec21), while the weak inhibitor 5-HelixV549D/L556A
exhibited a 100-fold lower kon value (0.028610
7 M21 sec21). Thus,
more rapidly associating 5-Helix variants had lower IC50 values,
independent of binding affinity. The data implied that 5-Helix
inhibition is kinetically restricted by the short exposure of its C-HR
binding site: more rapidly associating variants are more likely to
bind gp41 during the kinetic window of C-HR exposure. This
information enabled us to estimate that the C-HR is exposed for a
few seconds during the prehairpin intermediate state [3].
Because C37 inhibits the same intermediate state through a
complementary mechanism, we expected that its antiviral potency
should be similarly correlated with kon, and not KD. For a series of
C37 variants, IC50 values determined in viral infectivity assays
spanned more than four orders-of-magnitude, from 1.2 nM to
15 mM (Table S2, Figure S1). A similarly large range in KD values
(0.65 pM to 320 nM) was also measured. Contrary to our
expectations, generally good correlation was observed between
IC50 and KD values over this entire range (Figure 1C). By
contrast, C-peptide mutations had comparatively little impact
(,30-fold) on the rate of C37 association. Consequently, poor
correlation was observed between IC50 and kon values (Figure 1E).
Thus, C37 potency is primarily determined by equilibrium
binding affinity, in stark contrast to the kinetic dependence of 5-
Helix inhibition.
The disparity in the physical properties of C37 and 5-Helix
inhibition was not dependent on HIV-1 Env strain or coreceptor
utilization. The data in Figure 1 were generated using the
CXCR4-tropic, laboratory-adapted EnvHXB2, but qualitatively
similar results were obtained with the CCR5-tropic, primary
isolate EnvJR-FL: the potency of rapidly-associating 5-Helix
inhibitors was largely unaffected by affinity disruption, while the
potency of C37 variants was significantly reduced (Figure 2). A
dependence of inhibitory potency on binding strength has also
been observed for small D-peptides [24] and a monoclonal
antibody [25] that bind a deep hydrophobic pocket on the N-HR
coiled coil. Thus, affinity-dependent inhibitory potency appears to
be a general property of N-HR targeting inhibitors, irrespective of
inhibitor size and chemical nature. This contrast with the kinetic
properties of 5-Helix inhibition points to a fundamental mecha-
nistic difference between N-HR- and C-HR-targeting gp41
inhibitors.
Model of Intermediate-State Inhibition
Affinity-dependent inhibition by C37 implies that the C-
peptide/gp41 interaction is reversible, mimicking an equilibrium
process. By contrast, the kinetic dependence to 5-Helix inhibition
implies that the 5-Helix/gp41 interaction is functionally irrevers-
ible, as if 5-Helix association triggers rapid deactivation of gp41
before the inhibitor can dissociate. To account for the different
inhibitory properties of C37 and 5-Helix, we developed a single
quantitative model of intermediate state inhibition shown in
Author Summary
Blocking HIV-1 entry into host cells is a viable strategy to
prevent viral infection. Entry is mediated by viral surface
proteins gp120 and gp41, which undergo large structural
changes upon encountering the host cell. One critical
structural change involves the association of two distinct
gp41 regions, denoted N-HR and C-HR. Previous work
demonstrated that antivirals targeting the N-HR and C-HR
physically obstruct the association of these gp41 regions,
thereby preventing HIV-1 entry. Here, we show that these
inhibitors work through an additional mechanism—they
induce the irreversible deactivation of gp41. Furthermore,
the antiviral potency of these inhibitors is significantly
influenced by the speed of this irreversible deactivation.
When an inhibitor binds the C-HR, gp41 rapidly deactivates
before the inhibitor can efficiently dissociate. By contrast,
when an inhibitor binds the N-HR, gp41 deactivates very
slowly, allowing sufficient time for inhibitor dissociation
and resumption of gp41 structural changes. The disparity
in the rate of deactivation induced by N-HR- and C-HR-
targeting inhibitors reflects a fundamental difference in
deactivation mechanism. Thus, the results point to an
unappreciated asymmetry in gp41 following inhibitor
binding. Our findings are relevant to the development of
future entry inhibitors of HIV-1 and potentially other
viruses that utilize similar entry mechanisms.
Inhibitor-Mediated gp41 Deactivation
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Figure 3A (hereafter denoted Scheme 1). Here, N, I and F
symbolize the native, intermediate, and the fusogenic conforma-
tions of Env, respectively. The rate constants kon and koff describe
the kinetics of inhibitor (X) binding to I, where the equilibrium
dissociation constant KD equals koff/kon. The constant kf refers to
the unidirectional rate out of I and governs the lifetime of this
Figure 1. Inhibition of HIV-1 membrane fusion. (A) A working model of HIV-1 entry. Env subunit gp120 (green) interacts with cellular CD4
(orange), triggering gp41 to extend its N-terminus (red) toward the target cell membrane. Subsequent binding of gp120 to a chemokine receptor
(labeled coreceptor, purple) leads to collapse of the ectodomain into a trimer-of-hairpins and juxtaposition of viral and cellular membranes required
for fusion. Fusion inhibitors C37 and 5-Helix respectively bind the gp41 N-HR (gray) and C-HR (blue) segments transiently exposed during the
extended prehairpin state. (B–E) Affinity and kinetic dependence to 5-Helix (B, D) and C37 (C, E) inhibition. For series of inhibitor variants with
mutations in their gp41 binding sites, IC50 values are plotted as a function of KD or the inverse of kon. Each square represents a different inhibitor
variant and are color coded according to mutation class (see Tables S1 and S2). Gray circles in panels B and D correspond to inhibitory activities of 5-
Helix variants from previously reported cell-cell fusion experiments [3]. Please note that the axes of these plots are in logarithmic scale.
doi:10.1371/journal.ppat.1000674.g001
Inhibitor-Mediated gp41 Deactivation
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intermediate state. The constant ks describes the rate of
irreversible deactivation of the inhibitor-bound gp41 (I-X). Based
on this simple model of intermediate state inhibition, an equation
describing the IC50 value can be derived [3]:
IC50~
kf
kon
1z
koff
ks
 
ðEquation 1Þ
In the case when inhibitor dissociation is much slower than
gp41 deactivation (koff,,ks), the equation predicts that the IC50
values will vary inversely with the inhibitor association rate (IC50
> kf/kon). The dependence solely on kon is logical because virtually
every inhibitor association event leads to irreversible deactivation.
At the other extreme, when inhibitor dissociation occurs much
more rapidly than gp41 deactivation (koff..ks), the second term
in Equation 1 predominates, and the IC50 values depend on
binding strength (IC50 > kf KD/ks, where the ratio koff/kon was
replaced with KD). The dependence on KD in this situation is due
to the ability of the inhibitor to associate and dissociate numerous
times (the definition of equilibrium binding) before gp41 commits
irreversibly toward either its fusogenic or dead-end conformation.
Quantitative fits of IC50, KD and kon data to Equation 1 were
most remarkable for a 200-fold disparity in the deactivation rate (ks)
for C37 and 5-Helix inhibition (ks-C37 = 0.00049 sec
21; ks-5H=
0.11 sec21; Figure S2). The data suggest that the C37-bound
Figure 2. 5-Helix and C37 inhibition of primary isolate HIV-1 strain JR-FL. IC50 values for the wild type and lower affinity variants were
determined for HIV-1JR-FL infections of HOS-CD4-CCR5 cells (gray bars). For comparison, the IC50 values for HIV-1HXB2 infections of HOS-CDR-CXCR4
cells are also shown (hatched bars). The numbers below the axis labels are KD values (in nM) measured for binding to the HXB2 sequence. The arrow
indicates an IC50 value in excess of 20 mM.
doi:10.1371/journal.ppat.1000674.g002
Figure 3. Reversibility of gp41 inhibition. (A) Schematic of intermediate-state inhibition by C37 and 5-Helix. States and rate constants are
defined in the text. (B) Time course of recovery from C37 and 5-Helix inhibition. HIV-1 was preincubated 2 hours with target cells in the presence of
high inhibitor concentrations to trap gp41 in the inhibitor-bound state (I-X in Panel A). At time t = 0, cells were rapidly washed with virus-free,
inhibitor-free media to allow inhibitor dissociation and recovery of fusion activity. Infection was terminated by the addition of 1 mM C37 at various
times following this wash. The number above each C37 data set is the koff value for that C-peptide variant. (C) Dependence of reversibility on inhibitor
koff. Fraction recovery after 1 hour is plotted as a function of koff for C37 (square) and 5-Helix (triangle) variants numbered as follows: (1) di-C37, (2)
C37-KYI, (3) C37 WT, (4) C37I635A, (5) C37W628A, (6) C37L645D, (7) 5-Helix WT, (8) 5-HelixL556A/Q563A, (9) 5-HelixL556A/V570A, (10) 5-HelixL556A/Q563D. The data
represent the mean 6 SEM of three independent experiments.
doi:10.1371/journal.ppat.1000674.g003
Inhibitor-Mediated gp41 Deactivation
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intermediate state can persist in an inhibited but recoverable form
for an average of ,35 minutes, longer than the average bound
lifetime for most C37 variants (Table S2). By contrast, 5-Helix-
bound gp41 appears to undergo irreversible deactivation in ,10
seconds, shorter than the dissociation time constant for nearly all 5-
Helix variants (Table S1). Thus, the different inhibitory properties of
C37 and 5-Helix appear to reflect two extremes in the fate of Env
following inhibitor binding.
Recovery from Intermediate-State Inhibition
Our model predicts that C37 inhibition of HIV-1 entry is
reversible if the peptide dissociates before gp41 deactivates. To test
this prediction, we developed an inhibitor-washout viral infectivity
assay. HIV-1 infection was carried out in the presence of high
inhibitor concentration (.IC95) to trap CD4-engaged Env in the
inhibitor-bound intermediate state (I-X in Scheme 1). Following
this pre-incubation, culture media was rapidly exchanged with
inhibitor-free, virus-free solution that contained an anti-CD4
antibody to block new activation of any unengaged Env.
Successful viral infection, therefore, required inhibitor dissociation
from gp41 trimers that had not undergone deactivation. Fusion
activity recovered only slightly from inhibition by wild type C37,
which has a small koff compared to the gp41 deactivation rate
ks-C37 (0.00049 sec
21) (Figure 3B). However, fusion activity
showed greater and more rapid rebound for C37 variants with
larger koff values. This behavior reflects a kinetic competition
between C37 dissociation and gp41 deactivation: as koff increases,
the likelihood (and rate) of inhibitor dissociation increases,
resulting in greater (and faster) recovery of fusion activity.
Similar recovery of fusion activity was observed in inhibitor-
washout experiments employing PIE7, a small D-peptide that
targets the gp41 N-HR coiled coil (Figure S4). These data support
our conclusions that gp41 bound to an N-HR inhibitor persists for
an extended duration prior to deactivation. The reversibility of C-
peptide and D-peptide inhibition starkly contrasts the lack of
recovery from 5-Helix blockade (Figure 3B, C). The apparent
ks-5H (0.11 sec
21) is much greater than the koff values for the two 5-
Helix proteins that showed no fusion recovery in the washout
assay. For these molecules, inhibitor-bound Env is much more
likely to deactivate before 5-Helix dissociates. Even for 5-Helix
variants with koff values close to 0.1 sec
21, only a small amount of
recovery was observed, perhaps because most inhibitor-bound Env
had already deactivated before these 5-Helix variants were washed
away.
Design of ‘‘Irreversible’’ C37 Variants
Inhibition by high affinity 5-Helix variants is functionally
irreversible because gp41 deactivation occurs much more rapidly
than inhibitor dissociation. To test if extremely high affinity C-
peptides are similarly irreversible, we engineered four C37 variants
that bound more tightly to the gp41 N-HR coiled coil than wild
type C37 (Figure 4A). Three have point mutations in the Asn637/
Thr639 locus previously shown to enhance binding affinity 5- to
10-fold (HKS and MJR, submitted). The fourth is a dimeric C37
variant (denoted di-C37) that makes multivalent interactions with
the N-HR coiled coil. We observed no recovery from inhibition by
these tighter binding C-peptides, consistent with their reduced koff
values (Figure 3C). According to our model, such high affinity
peptides should be kinetically restricted inhibitors like 5-Helix; that
is, their potencies should be largely independent of binding affinity
(Equation 1 with koff,,ks). Indeed, against wild type HIV-1,
IC50 values for these engineered peptides (0.7 to 1.7 nM) were not
significantly different from the wild type C37 IC50 (Figure 4B).
Moreover, the antiviral activities of C37N637K/T639I (C37-KYI)
and di-C37 were much less sensitive to gp41 N-HR mutations that
disrupt inhibitor binding affinity. While the G547D/I548T and
V549E substitutions [26–28] conferred 40- to 120-fold resistance
to wild type C37, they had minimal impact on the potency of C37-
KYI and di-C37 (Figure 4C). Hence, binding strength plays a
greatly diminished role in determining the potency of kinetically
restricted C37 variants.
Impact of Chemokine-Receptor Binding on the
Deactivation of Inhibitor-Bound gp41
Chemokine-receptor levels on target cells influence the kinetic
properties of HIV-1 membrane fusion and the potency of gp41
inhibition [3,19,21]. We speculated that these levels might also
influence the rate of gp41 deactivation following inhibitor binding.
We compared C37 and 5-Helix inhibitory activity against HIV-
1HXB2 using target cells expressing low and high amounts of
CXCR4 (Figure 5). Lowering CXCR4 levels led to a 3.5-fold
increase in potency for the kinetically restricted inhibitors di-C37,
C37-KYI, and wild type 5-Helix. For 5-Helix inhibition, this
enhancement in potency was maintained for all variants, including
ones with koff values in excess of ks-5H. By contrast, IC50 values
were independent of CXCR4 levels for C37 variants with koff
values equal to or in excess of ks-C37. Qualitatively similar results
were obtained with HIV-1Ba-L using target cells expressing
different levels of CCR5 (Figure S5), suggesting that the observed
behaviors are general properties of C37 and 5-Helix inhibition.
Reducing surface expression of chemokine receptors slows down
Env-mediated membrane fusion, prolonging the average lifetime
of the inhibitor-sensitive intermediate [19]. The effect increases
the opportunity for C37 and 5-Helix to bind, thereby potentiating
inhibition. For kinetically restricted inhibitors, this potentiation
leads to enhanced potency (IC50 > kf/kon). For rapidly
dissociating inhibitors, however, this potentiation is modified by
any changes to the deactivation of inhibitor-bound gp41 (IC50 >
kf KD/ks). For these inhibitors, the dependence of potency on both
kf and ks reflects the likelihood that the bound-state deactivates
before the unbound state progresses toward fusion. For 5-Helix
inhibition, the degree of potentiation observed for the wild type
inhibitor is maintained for low affinity variants, suggesting that
reducing chemokine-receptor levels does not alter ks-5H. Con-
versely, inhibitor potentiation is lost for low affinity C37 variants,
implying that lowering chemokine receptor levels slows both kf and
ks-C37 to the same degree. Thus, these data strongly suggest that
deactivation of C37-bound gp41 involves chemokine-receptor
binding, while deactivation of 5-Helix-bound gp41 proceeds
through a completely different, chemokine receptor-independent
mechanism.
Asymmetric Exposure of the gp41 N-HR and C-HR
The differences in deactivation of C37- and 5-Helix-bound
gp41 led us to question whether these inhibitors actually target the
same intermediate state during viral entry. To test if the N-HR
and C-HR segments were exposed simultaneously, we explored
how well C37 inhibited when fusion was first trapped in the 5-
Helix-bound intermediate state. Using 5-HelixL556A/V570A (a 5-
Helix variant that exhibited appreciable recovery from inhibi-
tion—label 9 of Figure 3C), we performed a 5-Helix-washout viral
infectivity assay as previously described, except that C37 or
C37W628A was included in the washout solution. C-peptide
potency was improved 10- to 30-fold in these inhibitor-washout
experiments compared to standard inhibition experiments
(Figure 6A, Figure S6A). Such improvement in inhibitory potency
is inconsistent with C37 and 5-Helix binding to completely
independent states during the fusion process. Instead, C37 appears
Inhibitor-Mediated gp41 Deactivation
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to interact more efficiently with 5-Helix-bound gp41, perhaps
because the N-HR coiled coil is exposed for longer duration.
Curiously, when this experiment was carried out in reverse and
fusion was first trapped in the C37W628A-bound intermediate state,
the potency of 5-Helix inhibition showed comparatively little
enhancement (,2-fold, Figure 6B, Figure S6B). Thus, in contrast
with C37 binding to 5-Helix-trapped gp41, there appears to be no
substantial improvement in 5-Helix binding to the C37-trapped
state. This qualitative difference in trapped conformations suggests
that the gp41 N-HR and C-HR regions are not exposed
symmetrically in a single state during membrane fusion.
Asymmetric exposure of the gp41 N-HR and C-HR may also
explain the combined antiviral activity of C37 and 5-Helix. Since
wild type C37 and 5-Helix tightly associate at nanomolar
concentrations (KD= 0.65 pM), these two inhibitors are highly
antagonistic when used together [3,16], making them inappropri-
ate for combinatorial studies. Instead, we utilized C37N656D and 5-
HelixV549E because their binding affinity is relatively weak
(KD= 160 nM) compared to their individual inhibitory potencies
(see legend to Figure 6). With both inhibitors at low concentra-
tions, we observed additive antiviral activity, as if the inhibitors
targeted separate intermediate states (modeled by the solid line in
Figure 6C; for details, see Text S1 and Figure S7). At high
concentrations, the combined inhibitory activity showed consid-
erable synergy, as if the inhibitors bound simultaneously to a single
gp41 intermediate state (modeled by the dotted line in Figure 6C).
The gradual shift from additive to synergistic activity (Figure 6D)
suggests that neither model alone perfectly describes the inhibition
process. Rather, the data point to multiple prehairpin intermediate
conformations, some that exclusively bind C37 or 5-Helix and
others that can bind both inhibitors simultaneously.
Discussion
The growing class of intermediate-state inhibitors includes
antibiotics, immunosuppressive agents, and anesthetics used in the
research and clinical settings [1,2,29,30]. Also known as uncom-
petitive or use-dependent inhibitors, these agents bind transiently
accessible targets, and, accordingly, their potencies are not simple
functions of equilibrium binding affinity [31]. Kinetic parameters
such as the lifetime of the sensitive state and the rate of inhibitor
association can strongly influence the level of inhibition [3]. Here,
we have shown that the final disposition of the inhibitor-bound state
also critically affects the activity of intermediate state inhibitors.
Figure 4. Inhibitory activity of tighter-binding C37 variants. (A) Schematic of gp41 depicting the N-HR and C-HR segments, fusion peptide
(FP), transmembrane (TM), and cytoplasmic (Cyto) domains. The wild type C37 sequence below the diagram is derived from C-HR residues 625–661 of
HIV-1HXB2 gp41. The sequences of kinetically restricted variants C37N637K (KYT), C37T639I (NYI), C37N637K/T639I (KYI) are also shown with mutated
residues underlined. In the dimeric construct di-C37, two wild type peptides are crosslinked through C-terminal Cys residues. (B) Potency of high
affinity C37 variants against wild type HIV-1. IC50 data are plotted as a function of KD for wild type C37 (WT), C37-KYT, C37-NYI, C37-KYI and di-C37.
(C) Effect of affinity-disrupting N-HR mutations on C37 potency. IC50 values for C37 WT, C37-KYI, and di-C37 were determined for wild type Env
(black), EnvG547D/I548T (light gray) and EnvV549E (dark gray).
doi:10.1371/journal.ppat.1000674.g004
Inhibitor-Mediated gp41 Deactivation
PLoS Pathogens | www.plospathogens.org 6 November 2009 | Volume 5 | Issue 11 | e1000674
Inhibitor binding to the gp41 prehairpin intermediate state
promotes the irreversible deactivation of HIV-1 membrane fusion.
For C37-bound gp41, deactivation is a slow process, and most C37
variants have time to dissociate to some degree. Due to the
reversibility of inhibition, C37 potency depends upon binding
affinity for all but the tightest binding variants. Similar affinity
dependence has been observed for the potencies of other N-HR-
targeting inhibitors, including antibodies [25,32], D-peptides [24]
and other C-peptides [11,33]. This correlation suggests that slow
deactivation is a general property for inhibitors that target the
gp41 N-HR region. Conversely, 5-Helix-bound gp41 rapidly
deactivates before most 5-Helix variants have time to dissociate.
Consequently, 5-Helix inhibition is functionally irreversible, and
potency depends primarily on the rate of inhibitor association. It
remains to be seen whether rapid deactivation is a general
property for other engineered proteins and antibodies that target
the C-terminal region of the gp41 ectodomain.
C37-bound gp41 and 5-Helix-bound gp41 appear to deactivate
through distinct mechanisms that differ in both their time course
and chemokine-receptor dependence. For C37 inhibition, the
transition rate out of the unbound intermediate state and the
deactivation rate of the bound state (kf and ks-C37) are equally
sensitive to chemokine-receptor levels. Thus, chemokine-receptor
binding to gp120 appears to limit the lifetimes of both the
unbound and C37-bound states. The event likely alters the
association of gp120 and gp41, triggering TOH formation when
the N-HR is unbound, but causing gp41 to misfire when the N-
HR is bound. By contrast, the rapid deactivation rate of 5-Helix-
bound gp41 is independent of chemokine-receptor levels. Perhaps
5-Helix binding directly induces gp41 misfolding, possibly by
altering the manner by which the C-terminal region of the gp41
ectodomain interacts with gp120 or the viral membrane.
Alternatively, during the natural structural progression of the
prehairpin intermediate state, Env conformations might arise that
Figure 5. Effect of chemokine receptor density on 5-Helix- and C37-inhibitory activity against HIV-1HXB2. (A) Comparison of IC50 values
determined utilizing target cells expressing high (black) or low (gray) levels of CXCR4. Inhibitors are ordered according to increasing koff values. (B)
Ratio of the low-CXCR4 IC50 to the high-CXCR4 IC50 plotted as a function of inhibitor koff. Each data point reflects a unique C37 (squares) or 5-Helix
(circles) variant with error formally propagated. The gp41 deactivation rates (ks) for C37 and 5-Helix inhibition are indicated for comparative purposes.
doi:10.1371/journal.ppat.1000674.g005
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sterically block 5-Helix from dissociating, irreversibly trapping the
inhibitor on gp41. Whatever the mechanism, rapid, chemokine-
receptor independent deactivation may represent an advantageous
property to engineer into future HIV-1 membrane fusion
inhibitors.
The success of T20 (enfuvirtide) in the clinic has spurred
considerable efforts to design improved C-peptide inhibitors of
HIV-1 entry [33–37]. C-peptide variants have been engineered to
interact more strongly with the N-HR coiled coil, but none are
significantly more potent against wild type HIV-1 than the original
peptides. We suspect that these tighter binding variants are
kinetically restricted inhibitors much like C37-KYI and di-C37.
Their inhibition is effectively irreversible, and, consequently, their
potencies depend only on the lifetime of N-HR exposure and the
rate of inhibitor association. Interestingly, the potency of C-peptide
C34 against wild type HIV-1 strains is substantially improved (15 to
50-fold) when a cholesterol moiety is added specifically at the
peptide C-terminus [38]. Rather than increasing binding affinity,
the modification concentrates the peptide on target cell membranes,
optimally prepositioning the inhibitor to bind gp41 rapidly following
N-HR exposure. Hence, C-peptide potency can be improved by
increasing the rate of inhibitor association.
Although affinity enhancement does not improve their potency
against wild type virus, tighter binding C37 variants do represent
improved gp41 inhibitors. Escape from C-peptide inhibition
occurs largely through mutations in the N-HR segment that
directly disrupt peptide affinity [26–28,39,40]. The extra binding
strength of kinetically restricted inhibitors acts as a ‘‘resistance
capacitor’’ [24], enabling these peptides to retain their potency in
the setting of affinity-reducing escape mutations [28,34–36].
Consistently, we have found that resistance to C37-KYI and di-
C37 takes much longer to achieve and requires more escape
mutations than resistance to wild type C37 (KMK and MJR,
manuscript in preparation). Similar genetic barriers to resistance
have been reported for other second generation C-peptide
inhibitors [28,34,41].
Our synergy data suggest that C37 and 5-Helix can bind the
same gp41 intermediate, even though they promote Env
deactivation through different mechanisms. This prehairpin state,
however, probably does not adopt a single, static conformation
with the N-HR and C-HR regions symmetrically exposed.
Previous studies of lipid- and temperature-arrested Env suggest
that the intermediate conformation evolves, with the N-HR
becoming progressively exposed and the C-HR becoming
Figure 6. Overlap of the C37- and 5-Helix-sensitive intermediate states. (A) C37W628A inhibitory activity against HIV-1 by standard assay
(squares) or in a 5-Helix-washout assay after Env was first trapped in the 5-HelixL556A/V570A-bound state (circles). In the standard assay, C37W628A was
coincubated with virus and cells at the beginning of infection. In the 5-Helix-washout assay, target cells preincubated with HIV-1 and 5-HelixL556A/V570A
were washed with media containing C37W628A. (B) 5-HelixL556A/V570A inhibitory activity against HIV-1 by standard assay (squares) or in a C37-washout
assay after Env was first trapped in the C37W628A-bound state (circles). (C) Antiviral activity of C37N656D in the presence of 30 nM 5-HelixV549E. The
individual IC50 values for C37N656D and 5-HelixV549E were determined to be 130610 nM and 5462 nM, respectively. The solid line denotes the titration
expected if C37 and 5-Helix target separate intermediate states (additive inhibition). The dotted line denotes the titration expected if C37 and 5-Helix
could bind simultaneously to the same intermediate state (synergistic inhibition). These different binding scenarios are depicted schematically in Figure
S7, and their quantitative evaluations are presented in Text S1. (D) Concentration dependence to synergistic inhibitory activity. Combination indices
were calculated following the method of Chou and Talalay [49] for inhibition experiments performed with C37N656D and either 10 nM (circles) or 30 nM
(squares) 5-HelixV549E. A diminishing combination index below unity indicates increasing synergistic activity.
doi:10.1371/journal.ppat.1000674.g006
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progressively occluded [20]. These conclusions informed our
interpretation of the synergy data that C37 and 5-Helix target
partially, but not completely, overlapping states. What, then,
might account for this asymmetry in N-HR and C-HR exposure?
A possible candidate is gp120. A recent study of Env subunit
association suggests that CD4-bound gp120 can interact with
gp41-derived peptides containing the C-HR sequence [42]. A
similar association is not observed with N-HR-derived peptides.
Based on this result, we propose that an interaction between gp120
and the C-HR limits exposure of this gp41 segment after Env
activation. The presence of a bound 5-Helix would disrupt the
gp120/C-HR interaction, leading to chemokine receptor-inde-
pendent Env deactivation. By contrast, the N-HR coiled coil, once
formed, remains accessible to gp41 inhibitors until TOH
formation. With no competing interactions, the N-HR would
potentially tolerate a bound C-peptide until chemokine receptor
triggered the final gp41 conformational changes.
Materials and Methods
Cell Lines
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: HOS-CD4-Fusin and HOS-CD4-CCR5 from Dr.
Nathaniel Landau [43]; HeLa-CD4-LTR-b-gal from Dr. Michael
Emerman [44]. In addition, RC30 and RC49 were kindly
provided by Dr. David Kabat (Oregon Health Sciences Univer-
sity) [45].
Peptide and Protein Production
C37 is a His-tagged C-peptide derived from HIV-1HXB2 Env
residues 625–661 (Figure 4A) [16]. Wild type and mutant peptides
were generated through proteolysis of the recombinantly produced
trimer-of-hairpins construct NC1. This protein was expressed in
E.coli and purified from bacterial lysates using Ni-NTA Agarose
(Qiagen) per manufacturer’s protocol. Eluted NC1 was incubated
with trypsin (Sigma, 1:250 mass ratio) overnight at 4uC. The
resulting C37 was purified to homogeneity by reverse phase HPLC
(Vydac C18 column) using a water:acetonitrile gradient in
trifluoroacetic acid (0.1%). The identity of all C37 peptides was
confirmed by mass spectrometry.
5-Helix is a 25 kD His-tagged protein consisting of three N-HR
segments (EnvHXB2 residues 542–581) and two C-HR segments
(residues 625–662) alternately connected into a single polypeptide
[16]. This protein was recombinantly expressed in E.coli and
solubilized from bacterial inclusion bodies using 8 M guanidine
HCl (GdnHCl) in tris-buffered saline (TBS) [3]. Following initial
purification using Ni-NTA agarose, 5-Helix-bound beads were
heated to 90uC in 4 M GdnHCl and allowed to cool to room
temperature overnight to promote protein refolding. 5-Helix was
eluted with imidazole in TBS, and monomers were purified from
aggregates on a Sephacryl S200 HR column (GE). The concentra-
tions of all C37 and 5-Helix polypeptides were determined by
absorbance at 280 nm by the method of Edelhoch [46].
For interaction experiments, cysteinated versions of C37 and 5-
Helix were labeled with rhodamine- or fluorescein-maleimide
(Molecular Probes) [3]. C37 with an N-terminal Cys was labeled
prior to HPLC purification. 5-Helix with a C-terminal Cys was
labeled on beads under denaturing conditions prior to refolding.
The concentrations of these fluorescent polypeptides were
determined by absorbance using extinction coefficients of
87,500 M21 cm21 at 490 nm for fluorescein (in potassium
phosphate pH 9) and 95,000 M21 cm21 at 520 nm for rhoda-
mine (in methanol). These concentrations were verified through
stoichiometric titrations using unlabeled C37 and 5-Helix of
known concentrations.
Interaction Measurements
Reported KD and kon values were measured for the solution-
phase interaction of cognate-binding partners C37 and 5-Helix.
This interaction models C37 and 5-Helix binding to the gp41 N-
HR and C-HR, respectively. All experiments were carried out at
25uC in TBS supplemented with 100 mg/ml BSA, 0.02% NaN3,
and 1 mM PMSF. To determine C37 binding parameters, the
peptide was titrated into a fixed concentration of fluorescein-
labeled 5-Helix and incubated for 2.9 seconds for kinetic
measurements or for up to 72 hours for equilibrium measure-
ments. The concentration of unbound 5-Helix was determined
using a KinExA 3000 flow fluorimeter (Sapidyne Instruments)
with azlactone beads (Pierce) covalently coupled to C37 per
manufacturer’s protocol. 5-Helix captured by these beads led to a
change in bead fluorescence that was proportional to the unbound
5-Helix concentration in solution (Figure S1). The C37 concen-
tration dependence of the fluorescence signal was fit to a general
model of bimolecular interactions using manufacturer’s software.
5-Helix binding parameters were determined using similar
methods except that i) 5-Helix was titrated into a fixed
concentration of rhodamine-labeled C37, and ii) the beads were
covalently coupled to 5-Helix. Dissociation constants (koff) were
calculated using the equation koff =KDNkon. Details of these
binding assays can be found in reference [3].
Viral Inhibition Assay
C37 and 5-Helix inhibitory potencies were determined using
single-round viral infectivity assays as previously described [11].
Briefly, virions pseudotyped with EnvHXB2, EnvJR-FL or EnvBa-L
were generated by cotransfection of the Env-deficient HIV-1NL4-3
genome (pNL4-3R-E-Luc+ [47]) and an Env-expressing plasmid
(pEBB_Env) into 293T cells. HIV-1 harvested 48 hours post-
transfection was used to infect appropriate target cells (see below)
in the presence of varying inhibitor concentrations. The level of
viral infectivity was measured 48 hours later by assaying for
luciferase production in infected cells (Luciferase Assay System,
Promega). Data were fit to a Langmuir equation to obtain IC50
values (see Figure S1A).
Target cells expressed CD4 and varying concentrations of
CXCR4 (for EnvHXB2) or CCR5 (for EnvJR-FL and EnvBa-L). For
HIV-1HXB2 infections, we utilized HOS-CD4-CXCR4 (high
CXCR4) or HOS-CD4-CCR5 (low CXCR4) cells, which express
CXCR4 at levels of approximately 105 and 56103 molecules per cell,
respectively (HKS and MJR, unpublished results). For HIV-1Ba-L
infections, we utilized RC49 and RC30 cells, which express CCR5 at
levels of 8.56104 and 2.46103 molecules per cell, respectively [45].
By comparison, the typical range of endogenous expression is 103 to
104 CXCR4 molecules per cell (PBMCs [48]) and 26104 CCR5
molecules per cell (activated CD4+ human T-cells [45]). For
HIVJR-FL infections, we utilized HOS-CD4-CCR5 cells.
Inhibitor-Washout Viral Infectivity Assay
These experiments were designed to measure the reversibility of
C37 and 5-Helix inhibition. Care was taken to strictly maintain a
temperature of 37uC for all cellular washes and incubation steps.
HeLa-CD4-LTR-b-gal target cells were seeded in a 96-well plate at
1.66104 cells/well. The following day, these cells were preincubated
with HIV-1NL4-3 at 37uC in the presence of.IC95 concentrations of
C37 or 5-Helix. After 2 hours, cells were rapidly and thoroughly
washed (36100 ml, see Figure S3) with warm media containing no
gp41 inhibitor and 100 mg/ml of anti-CD4 antibody#19 (J. Hoxie,
Inhibitor-Mediated gp41 Deactivation
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University of Pennsylvania) to prevent activation of any unengaged
Env. These washout samples were incubated for varying times (0–
240 minutes) to permit inhibitor-bound Env to recover its fusion
activity. Additional preincubated samples were washed and
incubated in 1 mM C37 in order to measure the small level of
background infection that occurred during the 2-hour preincubation
phase. Infections were terminated upon the addition of 1 mM C37,
and cells were maintained another 24 hours to enable reporter
expression. Cell lysates (100 mM potassium phosphate, 100 mM
sodium phosphate, 0.1% triton, pH 7) were assayed for b-
galactosidase expression using Lumi-Gal 530 (Lumigen, Inc.). The
difference between the washout infection level and background
infection level reflects fusion recovery due to inhibitor dissociation.
Recovery fraction was calculated by normalizing this difference to
the infection level obtained when HIV-1 was preincubated in the
absence of inhibitor.
The assay was slightly modified to assess C37 and 5-Helix potency
against inhibitor-bound gp41. Following preincubation with
C37W628A or 5-HelixL556A/V570A, cells were washed with media
that contained the complementary inhibitor and incubated 1 hour.
Infections were terminated and subsequently analyzed as described
above. The dependence of recovery fraction on inhibitor concen-
tration was compared to standard titrations of HIV-1NL4-3 infectivity
(with virus and inhibitor coincubated for the duration of infection).
Supporting Information
Table S1 Inhibitory and binding properties of 5-Helix variants
Found at: doi:10.1371/journal.ppat.1000674.s001 (0.09 MB PDF)
Table S2 Inhibitory and binding properties of C37 variants
Found at: doi:10.1371/journal.ppat.1000674.s002 (0.10 MB PDF)
Text S1 Modeling the inhibitory activities of C37 and 5-Helix
combinations
Found at: doi:10.1371/journal.ppat.1000674.s003 (0.05 MB PDF)
Figure S1 Binding and inhibitory properties of selected C37
variants. (A) Inhibition of HIV-1 infectivity by C37 (black) and two
lower affinity variants, W628A (red) and L645D (green). Data are
representative of a single experiment and reflect the mean 6
ROM of duplicate measurements. Solid lines represent a fit of the
data to a Langmuir equation to obtain IC50 values. (B) KinExA
3000 fluorescence response to equilibrated solutions of 30 pM 5-
Helix-fluorescein and the shown concentrations of C37W628A. The
KinExA instrument was configured to capture a portion of
unbound 5-Helix within its flow cell in order to determine the free
5-Helix concentration in solution. The arrows labeled I and W
represent sample injection and buffer wash. (C) Titration of 30 pM
5-Helix-fluorescein (5H-F) by C37 (black), C37W628A (red) and
C37L645D (green). Data have been fit to a general bimolecular
equilibrium binding model to determine KD values. (D) KinExA
3000 fluorescence response to pre-equilibrated solutions of 1 nM
5-Helix-fluorescein and various concentrations of C37W628A.
Solutions were mixed for 2.9 seconds prior to passage through
the instrument flow cell. (E) Nonequilibrium titration of 1 nM 5-
Helix-fluorescein by C37 (black), C37W628A (red) and C37L645D
(green). Data have been fit to a kinetic bimolecular binding model
to determine kon values.
Found at: doi:10.1371/journal.ppat.1000674.s004 (0.38 MB PDF)
Figure S2 Affinity and kinetic dependence to antiviral potency.
IC50 values for the 5-Helix (A) and C37 (B) variants are plotted as a
function of both KD and kon. The data are color coded as in Figure 1
and globally fit to Equation 1 (blue mesh). The estimated kf and ks
values are: for C37, kf = 0.054 sec
21, ks-C37 = 0.00049 sec
21; for 5-
Helix, kf = 0.21 sec
21, ks-5H= 0.11 sec
21.
Found at: doi:10.1371/journal.ppat.1000674.s005 (0.80 MB PDF)
Figure S3 Assessment of inhibitor washout efficiency. Target
cells were incubated for 2 hours with high concentrations (.IC95)
of C37 variants (A) or 5-Helix variants (B) used in the inhibitor-
washout viral infectivity assay. The washout procedure (36100 ml
media) was performed and cells were subsequently infected with
HIV-1NL4-3 overnight. Measured viral infectivity was normalized
to a no-inhibitor control. Mean values 6 SEM for three
independent experiments are shown.
Found at: doi:10.1371/journal.ppat.1000674.s006 (0.20 MB PDF)
Figure S4 Recovery of gp41 fusion activity from PIE7 inhibition.
PIE7 is a short, rigid peptide composed of D-amino acids that targets
the deep hydrophobic pocket of the N-HR coiled coil [24]. A
crosslinked dimer of PIE7 inhibits HIV-1 entry more potently than
the monomeric form, presumably due to the enhanced binding
strength afforded by multivalent interactions. The timecourse of
fusion recovery from PIE7 (black) and PIE7-dimer (red) blockade
was measured as described in Figure 3, except that the virus used was
HIV-1HXB2 and the target cells were HOS-CD4-CXCR4. The
points represent the mean6ROMof two independent experiments.
Found at: doi:10.1371/journal.ppat.1000674.s007 (0.18 MB PDF)
Figure S5 Effect of CCR5 levels on 5-Helix- and C37-inhibitory
activity against HIV-1Ba-L. IC50 values were determined utilizing
RC49 (black) and RC30 (gray) target cells expressing high and low
levels of CCR5, respectively (see Materials and Methods). Inhibitors
are ordered according to increasing koff values as measured for
HXB2 sequences. The data represent the mean 6 SEM of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1000674.s008 (0.19 MB PDF)
Figure S6 Sensitivity of inhibitor-trapped gp41 to wild type C37
and 5-Helix. (A) C37 inhibitory activity was measured by standard
assay (squares) or in a 5-Helix-washout assay after Env was first
trapped in the 5-HelixL556A/V570A-bound state (circles). (B) 5-Helix
inhibitory activity was measured by standard assay (squares) or in a
C37-washout assay after Env was first trapped in the C37W628A-
bound state (circles). Experiments were conducted as described in
the legend to Figure 5.
Found at: doi:10.1371/journal.ppat.1000674.s009 (0.18 MB PDF)
Figure S7 Simulating the combined inhibitory activities of 5-
Helix and C37. (A, B, C) Models of intermediate state inhibition by
two different inhibitors X and Y. In Model 1 (A), the inhibitors bind
separate states. In Model 2 (B), the inhibitors bind separately to the
same state. InModel 3 (C), the inhibitors can bind simultaneously to
the same state. (D, E, F) Monte Carlo simulation of the inhibitory
activities of 5-HelixV549E and C37N656D alone (symbols). The solid
lines correspond to the expected titrations based upon the respective
IC50 values (54 nM for 5-HelixV549E; 130 nM for C37N656D) and
calculated using a Langmuir function (Equation S1, see Text S1).
(G, H, I) Monte Carlo simulation of the C37N656D inhibitory activity
in the presence of 30 nM 5-HelixV549E. Solid lines correspond to the
analytical solution of fusion probability for Models 1 and 2
(Equations S2 and S3). Simulated points represent the average of
105 iterations. The interaction between 5-HelixV549E and C37N656D
(KD=165 nM) was taken into account for all simulations and
calculations. Details of the simulation procedure and derivation of
the analytical formulas are presented in Text S1.
Found at: doi:10.1371/journal.ppat.1000674.s010 (0.25 MB PDF)
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